Leerink Partnrs Issues Positive Outlook for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Research analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for Alnylam Pharmaceuticals in a report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will post earnings of ($0.72) per share for the quarter, up from their previous […]